Preoperative serum placenta growth factor level is a prognostic biomarker in colorectal cancer
Journal
Diseases of the Colon and Rectum
Journal Volume
52
Journal Issue
9
Pages
1630-1636
Date Issued
2009
Author(s)
Abstract
PURPOSE: Increased angiogenesis at the site of the primary tumor in colorectal cancer has been associated with poor prognosis and relapse of disease. We previously demonstrated that the tissue level of placenta growth factor expression was upregulated in colorectal cancer and correlated with disease progression and patient survival. The aims of this study are to examine the prognostic value of serum placenta growth factor, vascular endothelial growth factor, and sFlt-1 and to compare them with the carcinoembryonic antigen levels in patients with colorectal cancer. METHODS: Preoperative serum from 86 patients and serum from 30 healthy controls was included. The levels of sFlt-1, placenta growth factor, vascular endothelial growth factor in the serum were assayed and correlated with the clinical stage results. RESULTS: Serum placenta growth factor, but not vascular endothelial growth factor, increased; sFlt-1 decreased in patients with preoperative colorectal cancer, compared with healthy controls. Higher preoperation serum placenta growth factor levels were associated with higher risk of recurrence. Preoperation serum placenta growth factor, but not carcinoembryonic antigen, was a prognostic indicator in patients with Stage III colorectal cancer. When we use the median level (20.6 pg/ml) of preoperative serum placenta growth factor as a cutoff point, the sensitivity, specificity, and positive predictive value for tumor recurrence and survival was 80, 54, 80% and 70, 56, 70%, respectively. CONCLUSIONS: Preoperative serum placenta growth factor levels were higher in patients with colorectal cancer, were negatively correlated with the serum sFlt-1, and could be used as a prognostic indicator for recurrence and survival for colorectal cancer. ? 2009 The ASCRS.
SDGs
Other Subjects
biological marker; carcinoembryonic antigen; placental growth factor; vasculotropin; vasculotropin receptor 1; carcinoembryonic antigen; FLT1 protein, human; placenta protein; product placenta growth factor; vasculotropin A; vasculotropin receptor 1; VEGFA protein, human; adult; aged; angiogenesis; article; cancer growth; cancer patient; cancer relapse; cancer staging; cancer survival; colorectal cancer; controlled study; female; human; major clinical study; male; preoperative period; prognosis; protein blood level; recurrence risk; sensitivity and specificity; upregulation; blood; case control study; cohort analysis; colon tumor; middle aged; mortality; prediction and forecasting; rectum tumor; Adult; Aged; Aged, 80 and over; Carcinoembryonic Antigen; Case-Control Studies; Cohort Studies; Colonic Neoplasms; Female; Humans; Male; Middle Aged; Predictive Value of Tests; Pregnancy Proteins; Prognosis; Rectal Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1
Type
journal article